How many insider trades does FilingIQ track for REVB?

FilingIQ tracks 40 Form 4 insider transactions for REVB (REVELATION BIOSCIENCES, INC.), covering filings from Feb 4, 2022 onwards. 2 of those were filed in the last 90 days.

Are REVB insiders net buyers or net sellers?

Across the full Form 4 history for REVB, 10 transactions (25%) were open-market purchases and 7 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does REVB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is REVB in?

REVELATION BIOSCIENCES, INC. (REVB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.91M.

REVB insider trading

Healthcare

REVELATION BIOSCIENCES, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

25% / 18%

Market cap

$3.91M

About REVELATION BIOSCIENCES, INC.

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Company website: www.revbiosciences.com

REVB insider activity at a glance

FilingIQ has scored 40 insider transactions for REVB since Feb 4, 2022. The most recent filing in our index is dated Apr 30, 2026.

Across the full history, 10 open-market purchases and 7 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on REVB insider trades is 63.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live REVB trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for REVB?: FilingIQ tracks 40 Form 4 insider transactions for REVB (REVELATION BIOSCIENCES, INC.), covering filings from Feb 4, 2022 onwards. 2 of those were filed in the last 90 days.
Are REVB insiders net buyers or net sellers?: Across the full Form 4 history for REVB, 10 transactions (25%) were open-market purchases and 7 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does REVB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is REVB in?: REVELATION BIOSCIENCES, INC. (REVB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.91M.

Methodology & sources

Every REVB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.